Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 1 2Glioma 2Colorectal Neoplasms 2Vascular Malformations 1Skin Diseases, Vascular 1Primary Malignant Peripheral Nerve Sheath Tumors 1Oligodendroglioma 1Neurofibromatoses 1Neurofibroma 1Neurocytoma 1Neoplasms, Neuroepithelial 1NF1 1Melanoma 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Liposarcoma, Myxoid 1Liposarcoma 1KRAS Mutant Non-Small Cell Lung Cancer 1Glioblastoma 1Ganglioneuroma 1Ganglioglioma 1Central Nervous System Neoplasms 1Breast Neoplasms 1Astrocytoma 1Arteriovenous Malformations 1

Interventions

mirdametinib 1gallium Ga 68 dotatate 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ga(III)-DOTATOC 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Ganglioneuroma × mirdametinib × Clear all
NCT04923126 2026-02-04

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
132 enrolled
CNS

Astrocytoma, Ganglioneuroma, Oligodendroglioma, Neoplasms, Neuroepithelial, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡